P3.01-56 Hyperprogression and Pseudoprogression in Patients With Non-Small Cell Lung Cancer on Checkpoint Blocking Immunotherapy

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.1616
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pseudoprogression in Non–Small Cell Lung Cancer Upon Immunotherapy: Few Drops in the Ocean?

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

P3.01-19 Sequencing of Ramucirumab+Docetaxel Post-Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Patients

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-36 Prognostic Factors in Elderly Patients With Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-11 Depression and Inflammation in Patients With EGFR-Mutated Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Review of Checkpoint Immunotherapy for the Management of Non-Small Cell Lung Cancer

ImmunoTargets and Therapy
AllergyImmunology
2018English

P3.01-31 Prognostic Factors in Patients With Resected Pathological N2 Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

FDA Approves Breakthrough Immunotherapy for Patients With Non-Small-Cell Lung Cancer

Cancer
Cancer ResearchOncology
2017English

Immune-Checkpoint Inhibitor Treatment of Non-Small Cell Lung Cancer Patients

Jurnal Respirasi
2020English

18f-Fet PET for Diagnosis of Pseudoprogression of Brain Metastases in Patients With Non–Small Cell Lung Cancer

Clinical Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy